Kornimate/medical-research-clean huggingface dataset:
unc pleural fluid registry

Conditions: Lung Cancer; Lung Infection; Breast Cancer; Malignant Pleural Effusion; Empyema

Summary: research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. the purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. the information learned from the biospecimens may be used in future treatments. the purpose of this protocol is to create a pleural fluid registry for use in future studies.


Eligibility criteria:
inclusion criteria: * patients who are 18 years or older * inpatients and outpatients * diagnosed with pleural fluid, are referred for and undergo clinically indicated drainage who have clinical evidence of: * pulmonary infection (such as fever, leukocytosis, new or worsening infiltrate on chest x-ray, or clinical deterioration) with effusion * malignancy exclusion criteria: * a subject will not be eligible for inclusion in this registry if, in the investigator's (or treating clinician's) opinion, the patient has any concurrent medical condition that may preclude their ability to undergo pleural fluid drainage safely. * incarcerated individuals

Keywords: biospecimen pleural fluid lung cancer cancer infection breast cancer
reacto & immunogenicity of tf formulation of influsplit ssw® 2002/03 v/s std formulation of influsplit ssw® 2002/03

Conditions: Influenza

Summary: this is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of influsplit ssw® 2002/2003 versus the standard formulation of influsplit ssw® 2002/2003 in individuals over 18 years.


Eligibility criteria:
inclusion criteria: * healthy subjects who are capable of being vaccinated and subjects with primary diseases (cardiovascular conditions, metabolic conditions such as diabetes mellitus, respiratory diseases) who are capable of being vaccinated and aged over 18 years who want to be vaccinated against influenza or for whom the doctor considers prophylactic influenza immunisation to be indicated. * the inclusion of individuals who had not been immunised in the 2001/2002 season is preferred. * written consent to vaccination must be available after the subjects have been briefed on the study in understandable language. exclusion criteria: * use of study or unlicensed medication or administration of a vaccine other than the study vaccine within 30 days preceding vaccination and/or during the study period * acute disease at the beginning of the study * acute clinically significant changes in the lungs, cardiovascular system, liver or kidney function, identified by physical examination or laboratory tests * pregnancy * women who would like to fall pregnant during the period from the day of vaccination to 1 month thereafter * known allergic reactions that might have been caused by one or more ingredients of the vaccine

Keywords: influenza thiomersal-free influenza split vaccine 2002/2003 influsplit ssw®/fluarix™ 2002/2003
the effects of inhaled nitric oxide after fontan operation

Conditions: Congenital Heart Defect

Summary: pleural effusions continue to be a post-operative complication seen after fontan operation. this study will examine the use inhaled nitric oxide (ino) given for 54 hours after fontan operation to improve fluid balance. the study hypothesis is that inhaled nitric oxide after fontan operation will improve fluid balance, thus decreasing the incidence of pleural effusions and shortening hospital stay.


Eligibility criteria:
inclusion criteria: * male/female patients * undergoing fontan operation at the nemours cardiac center at a. i. dupont hospital for children * written parental permission to participate in this research study exclusion criteria: * any condition which the pi feels will interfere with the patient's safe and effective participation

Keywords: fontan
male reproductive health of floating population: a large-scale survey in dongguan

Conditions: Sexual Behavior; Erectile Dysfunction; Premature Ejaculation

Summary: to determine the prevalence of sexual problems particularly premature ejaculation and erectile dysfunction among men working in factories of dongguan city, using the self-rating scales like international index of erectile function, and to investigate the characteristics or risk factors associated with these sexual problems in floating population through regression analysis.

in china, the floating population is a special group of people who work and live outside their hometowns and without residence cards of that area they reside. sexual problems are common in floating population, majority of whom are in their sex active age. there is a lack of studies concerning these sexual problems, so we conduct this survey to investigate the sexual dysfunctions among men, especially the floating population, and to find out whether most of these sexual problems are related to their social lives, medical illnesses, and psychological status.

Eligibility criteria:
inclusion criteria: * have reached 18 years old * live in dongguan more than 6 months * floating population * with or without residence card exclusion criteria: * younger than 18 years old * live in dongguan less than 6 months

Keywords: male reproductive health floating population sexual behavior erectile dysfunction premature ejaculation
global study looking at the combination of rad001 plus best supportive care (bsc) and placebo plus bsc to treat patients with advanced hepatocellular carcinoma.

Conditions: Carcinoma

Summary: the purpose of this study is to compare treatment with rad001 plus best supportive care (bsc) to placebo plus bsc in patients with advanced hcc whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.


Eligibility criteria:
inclusion criteria: * advanced liver cancer * prior systemic treatment with sorafenib for advanced hcc and for whom their disease progressed during or after sorafenib treatment, or were intolerant to sorafenib treatment. specifically, this can be defined as: * documented radiological confirmation (radiology scans or report) of disease progression during or after sorafenib treatment * intolerance to sorafenib (at any dose and/or duration) is defined as documented sorafenib-related grade 3 or 4 adverse events that led to sorafenib discontinuation. note: * sorafenib must be the last antineoplastic treatment before randomization * prior local and/or hormonal therapy (e.g., tamoxifen) before sorafenib is allowed * one systemic chemotherapy regimen for advanced hcc is allowed before sorafenib treatment * ecog performance status of ≤ 2 * child-pugh a exclusion criteria: * active bleeding during the last 28 days * prior therapy with mtor inhibitors * prior liver or other organ transplantation which mandates systemic immunosuppression other protocol-defined inclusion/exclusion criteria may apply

Keywords: hepatocellular carcinoma randomized trial medical treatment rad001 placebo advanced hepatocellular carcinoma (hcc)
methocarbamol in ventral and inguinal hr

Conditions: Ventral Hernia; Inguinal Hernia

Summary: the purpose of this study is to gather information on methocarbamol as a pain management treatment for ventral or inguinal hernia repair. methocarbamol has been part of the pain management treatment for both inpatient and outpatient procedures at prisma health. this study will compare the outcomes of patients who receive methocarbamol, those who receive the standard opioid pain management treatment, and those who receive methocarbamol plus the standard opioid pain management treatment. participants will be randomized into one of the study groups listed below. primary ventral hernia repair or inguinal hernia repair: group 1: standard opioid after surgery group 2: methocarbamol after surgery open or robotic ventral hernia repair outpatient: group 1: standard opioid after surgery group 2: standard opioid plus methocarbamol after surgery open or robotic ventral hernia repair inpatient: group 1: standard opioid at discharge group 2: standard opioid plus methocarbamol at discharge a total of 200 participants will be included in the study. participation will last for about 30 days after surgery.


Eligibility criteria:
inclusion criteria: * \>18 y/o * patients undergoing open primary ventral hernia repair (group 1) * patients undergoing inguinal hernia repair (open, laparoscopic, or robotic; group 2) * patients undergoing open incisional hernia repair (group 3) * robotic repair ventral or incisional hernias (group 4) * given consent for randomization exclusion criteria: * \<18 y/o * pregnancy * chronic opioid users
hydrocoil cerebral aneurysm treatment trial

Conditions: Intracerebral Aneursym

Summary: the study will compare clinical and angiographic outcomes in patients receiving hydrocoil aneurysm treatment versus patients receiving non-hydrocoil aneurysm treatment.

with prospective, randomized trials in progress evaluating the effectiveness of hydrocoils and cerecyte coils in comparison to bare platinum coils, the next step is a direct comparison of hydrocoils and non-hydrocoils (cerecyte or platinum). considering the increased costs to society of treatment with these new coils, it is essential that the benefits of the new technology are properly evaluated against the existing platinum coil technology in a scientifically valid manner.

Eligibility criteria:
inclusion criteria: 1. patient presenting with a ruptured or un-ruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neurovascular team (neurosurgeon/neurointerventionalist) 2. the neurointerventionalist believes that the aneurysm can be safely treated with either cerecyte or hydrogel. 3. patients between (and including) 21 and 90 years of age. 4. patient hunt and hess grade 0-3. 5. patient has given fully informed consent to endovascular coiling procedure. if patient cannot consent for themselves, appropriate written consent has been sought from their next of kin, or from appropriate power of attorney. 6. aneurysm 5-20mm in maximum diameter. 7. patient is willing and able to return for clinical evaluation and follow-up imaging evaluation (angiography or mra) at both 6-months and 12-18 months after endovascular treatment. 8. the patient has not been previously randomized into this or another related ongoing trial. 9. the aneurysm has not previously been treated (by coiling or clipping). exclusion criteria: 1. patient has more than one aneurysm requiring treatment in the current treatment session if a patient has multiple aneurysms, but only one will be treated at the time of enrollment, they are eligible for the trial. (additional aneurysms may be treated at a later date, and may be treated with any coil type that the operator chooses). 2. target aneurysm has had previous coil treatment or surgically clipped. 3. patient has an h\&h score of 4 or 5 after subarachnoid hemorrhage (sah). 4. inability to obtain informed consent. 5. medical or surgical co-morbidity such that the patient's life expectancy is less than 1 year. -

Keywords: stent cerebral aneursym neurology radiology
physical function and activities of daily living in cancer patients during chemotherapy

Conditions: Advanced Gastrointestinal Cancer

Summary: the study is a randomized controlled trial with the aim to examine the feasibility and the effects of a home-based exercise intervention program on activities of daily living (adl) in patients with advanced gastrointestinal cancer undergoing chemotherapeutic treatment. further outcomes include functional and body status, quality of life, body composition, and chemotherapy completion rate. study participants will be randomized to an exercise intervention group or a wait-list control group

a randomised longitudinal study. a total of 44 gastrointestinal cancer patients before their first-line chemotherapy are recruited and randomised into one of two treatment groups a: home based- physical activity or b: wait-control. the intervention period is 12 weeks. primary outcome are the adls (iadl 1-8; fim 1-7).secondary outcomes are the physical activity, quality of life, peripheral polyneuropathy, chemotherapy regimen, gait speed, postural stability, maximal isometric voluntary force of the upper extremity, maximal isometric voluntary force (mivf) and strength endurance of the lower extremity, nutritional state, body composition and perceive functional ability. all measurements are standardized and are performed before chemotherapy, after 2 cycles of chemotherapy (4-6weeks) and after 12 weeks.

Eligibility criteria:
inclusion criteria: * histologically classified gastrointestinal cancer * uicc iii-iv * prior to (planned) first-line chemotherapy (curative und palliative) * ≥50 years exclusion criteria: * ecog \> 2 * systemic diseases (ms, als) * disorders (neurological, skeletal, muscular, mental or cognitive) or drug use (irrespective of the cancer therapy) that may affect gait, balance or muscular strength * chronic infection, uncontrolled hypertension (diastolic pressure over 95 mmhg) * vestibulopathies * uncorrected visual deficits
effect of intensified physical activity for patients with stroke - a combined physical and behavioural approach

Conditions: Stroke

Summary: chronic conditions such as stroke are associated with physical disability and an economic burden for the family and the society. a medical approach is often not sufficient to address the bio-psychological process of chronic disease. behavioural medicine approaches are often needed to improve the treatment outcomes. those approaches have often successfully been used together with physical activity to change health behaviour in inactive individuals and in pain management. in this project the combined approach of behavioural medicine principles and physical training will be tried on patients who have had a stroke one year ago where it has yet only been used scarcely. as the study focus on the individuals' ability to function and be active the primary outcome measure is disability. the aim of the study are in a randomized controlled study evaluate if a high intense functional exercise program as an group intervention under three months can influence functional, psychosocial, anthropometric and biochemical factors 3, 6 months and 1 year after the start of the study. following outcome variables will be analyzed: 1. level of physical activity, motor function and balance 2. depression and health-related quality of life 3. body mass index (bmi), metabolic risk profile, inflammation status 4. number of falls, fall-related self-efficacy and outcome expectations

hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. all exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. hife are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. the exercises will be progressively increased in load and difficulty.

Eligibility criteria:
inclusion criteria: * patient with first-ever stroke in the age of 65-65 years getting their stroke at least one year ago and living in the community. exclusion criteria: * other illness or disability that have an impact on the activity level and participation in tests beside problems after stroke.

Keywords: stroke physical activity balance muscle-strength
task specific training for advanced multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to find effective physical therapy treatments for individuals who have severe multiple sclerosis. physical therapy treatments for mild-to-moderate multiple sclerosis exists, however, very limited research has been done for physical therapy for severe multiple sclerosis (ms). in this study 10 participants diagnosed with severe ms will engage in 1-hour physical therapy sessions twice a week for 6 weeks to address limitations in standing, balancing, and bed mobility.

the purpose of this study is to investigate the feasibility, safety, and efficacy of task-specific physical therapy for persons with severe ms. the hypothesize for this study that a task-specific physical therapy program is safe, feasible, and effective in persons with severe ms. multiple studies have confirmed the effectiveness of task specific physical therapy for persons with ms. however,ms is a progressive disease which can lead to mild to severe disability and the studies examining the effectiveness of task specific therapy have only been conducted on persons with mild to moderate ms impairments. the small amount of research on physical therapy for persons with severe disability due to ms has only looked at the use of generalized conditioning exercises(1). task specific therapy has been shown to be effective in persons with severe disability in non-ms neurologic disorders.(2) the effectiveness of task specific exercises on persons with severe ms not been studied. based on the previous scientific evidence of the effectiveness of task-specific physical therapy in ms subjects with mild-to-moderate disability, there is strong scientific justification for conducting a trial of task specific therapy on persons with severe disability due to ms. the results of this study will be presented at various conferences attended by physical therapists as well as other health care practitioners who specialize in ms care, including the american physical therapy combined sections meeting, as well as the consortium of multiple sclerosis centers annual meeting. additionally, upon completion of the study, we will submit a manuscript to the appropriate peer review journal.

Eligibility criteria:
inclusion criteria: 1. definitive diagnosis of multiple sclerosis 2. expanded disability status scale (edss) of 7.0-8.0 3. ability to read, understand , and sign an informed consent - exclusion criteria: 1. evidence of ms exacerbation in the 4 weeks prior to starting the study 2. any orthopedic, cardiopulmonary, or non-ms neurologic symptoms that will interfere with their ability to participate in the study
efficacy and safety of anticoagulant therapy in portal vein thrombosis

Conditions: Liver Cirrhosis; Portal Vein Thrombosis

Summary: the study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (pvt).

portal vein thrombosis (pvt) is a frequent complication of liver cirrhosis, referred to partial or complete thrombosis formed in the lumen of portal vein or/and branches of it. currently, clinical guidelines of pvt in cirrhotic patients has not been addressed, and anticoagulant therapy of pvt patients with cirrhosis remains controversial. although numerable studies have reported that anticoagulation therapy is effective, while a majority of them were respective and a few took control into consideration. in addition, no agreement has reached about the safety of anticoagulation. so, the efficacy and safety of anticoagulant therapy needs more prospective randomized controlled trial to be investigated.

Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * liver cirrhosis diagnosis based on clinical, laboratory, and imaging studies, and pvt diagnosed by abdominal contrast-enhanced computed tomography, contrast-enhanced mri, or portal angiography exclusion criteria: * cavernous transformation of the portal vein * uncontrolled active bleeding * platelet count lower than 10\*10\^9/l * creatinine more than 170 mmol/l * ongoing or received antithrombotic/thrombolytic treatment * primary thrombophilia * budd-chiari syndrome * pregnancy or breast-feeding period * severe cardiopulmonary diseases * severe systemic infection or sepsis * inability to sign informed consent

Keywords: portal vein thrombosis nadroparin calcium warfarin anticoagulation
cost-effectiveness analysis of rotavirus vaccination for children in korea

Conditions: Gastroenteritis; Rotavirus Vaccines; Cost-Effectiveness

Summary: the primary objective of the proposed project is to estimate the economic impact of a national rotavirus immunization program in preventing rotavirus diarrhea among korean children.

rotavirus is the leading cause of severe acute diarrhea or gastroenteritis among young children worldwide. in the first 5 years of life, about 90% of children experience at least one episode of rotavirus infection.each year, rotavirus diarrhea is responsible for 440,000 deaths, 2 million hospitalizations, and 25 million outpatient visits among children younger than 5 years worldwide. in south korea, rotavirus diarrhea rarely causes mortality, but it cause significant morbidity. a recent population-based study in korea has estimated that the annual incidence of rotavirus diarrhea accounts for 56.9 cases per 1,000 children less than 5 years old. oral, live pentavalent human-bovine reassortant rotavirus vaccine has been developed and licensed for the use of preventing rotavirus disease in many countries. yet, there has been no research done to assess the impact of national rotavirus immunization program in korea. it is expected that systematic appraisal on the national burden of rotavirus infection and potential public health and economic benefits of rotavirus vaccination for children in korea will assists health policy makers to set a priority for the prevention of this disease.

Eligibility criteria:
inclusion criteria: * children aged under 5 years and diagnosed as acute gastroenteritis exclusion criteria: * none

Keywords: cost effectiveness analysis of rotavirus vaccination
development of the general scale observance for chronic diseases

Conditions: Chronic Diseases

Summary: the main objective is to assess the measurement characteristics (validity, reproducibility) and the invariance of egomac scale in a population of consultants in diabetology, cardiology and rheumatology hospital and liberal and hospital oncology and infectious disease, by following the evolution of patient compliance at d0 and d15. the second objective is to assess the sensitivity to change of scale egomac following developments compliance 3 months.

during a routine appointment (d0), the patient filled a newsletter and a questionnaire to complete. the doctor collects medical informations for the case report form. at the end of the first consultation (d0), an additional egomac scale and a stamped envelope is delivered to the patient by asking him to fill that scale to 15 days and return it by post office (reproducibility study). finally, a new scale will be addressed to the patient at the end of 3 months, which will return by post office too (stability study).

Eligibility criteria:
inclusion criteria: * patient age of 18 years * from routine patient counseling * with at least one of these diseases : heart failure, hypertension, coronary disease, type 2 diabetes, osteoarthritis of the knee or hip, osteoporosis, inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy), cancer ( with only non-hormonal oral anti cancer treatments) and hiv. * patient can read the french language in order to complete the self -administered questionnaire * patient agreeing to participate in the study exclusion criteria: * patient treated for more than 3 conditions mentioned in the inclusion criteria ( * patient receiving no drug prescription or recommendation of lifestyle or diet (for example consultationpurely diagnostic ).